Barclays
LUCD icon

Barclays’s Lucid Diagnostics LUCD Stock Holding History

Barclays’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5K Buy
26,590
+10,137
+62% +$10.9K ﹤0.01% 4508
2026
Q1 		$18.9K Sell
16,453
-124,714
-88% -$159K ﹤0.01% 4587
2025
Q4 		$154K Buy
141,167
+40,891
+41% +$45.7K ﹤0.01% 4439
2025
Q3 		$101K Sell
100,276
-19,726
-16% -$21.5K ﹤0.01% 4612
2025
Q2 		$138K Buy
120,002
+118,418
+7,476% +$153K ﹤0.01% 4491
2025
Q1 		$2.36K Buy
+1,584
New +$1.9K ﹤0.01% 4984
2022
Q2 		– Sell
-822
Closed -$2K – 5164
2022
Q1 		$2K Buy
+822
New +$3K ﹤0.01% 4787

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Barclays's LUCD Position: Q2 2026 in Review

Barclays increased its Lucid Diagnostics (LUCD) stake by 62% in Q2 2026, buying an estimated $10.9K and bringing the position to 26,590 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4508.

Barclays first reported a position in LUCD in Q1 2022 and has held it in 7 quarters since. The position peaked at $154K in Q4 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Barclays held 26,590 shares of Lucid Diagnostics worth $28.5K as of Q2 2026.
  • Barclays bought 10,137 Lucid Diagnostics shares in Q2 2026, an estimated $10.9K.
  • Lucid Diagnostics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4508 holding.
  • Barclays first reported a position in Lucid Diagnostics in Q1 2022 and has held it in 7 quarters since.
  • Barclays's Lucid Diagnostics position peaked at $154K in Q4 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.